cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Eagle Pharmaceuticals Inc
1 own
12 watching
Current Price
$31.16
$-0.66
(-2.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
405.57M
52-Week High
52-Week High
53.78
52-Week Low
52-Week Low
24.35
Average Volume
Average Volume
0.1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
37.5328
iconMarket Capitalization405.57M
icon52-Week High53.78
icon52-Week Low24.35
iconAverage Volume0.1M
iconDividend Yield--
iconP/E Ratio37.5328
What does the Eagle Pharmaceuticals Inc do?
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Read More
How much money does Eagle Pharmaceuticals Inc make?
News & Events about Eagle Pharmaceuticals Inc.
Globe Newswire
5 months ago
WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delawares decision that Eagles vasopressin product ...
Ticker Report
8 months ago
BNP Paribas Arbitrage SA lessened its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) by 45.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 6,397 shares of the specialty pharmaceutical companys stock after selling 5,396 ...
Ticker Report
8 months ago
Principal Financial Group Inc. decreased its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) by 10.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 87,897 shares of the specialty pharmaceutical company&#...
Ticker Report
10 months ago
Equities analysts forecast that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) will report earnings per share of $3.91 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Eagle Pharmaceuticals earnings, with estimates ...
Globe Newswire
10 months ago
Expects to add two U.S. Food and Drug Administration (FDA)-approved, new chemical entities (NCEs) with patent life into 2031 and expand acute care footprintCommercialized assets, BARHEMSYS (amisulpride for injection) and BYFAVO (remimazolam for injection), represent a strong strategic fit with ...
Frequently Asked Questions
Frequently Asked Questions
What is Eagle Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Eagle Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Eagle Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Eagle Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Eagle Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Eagle Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Eagle Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Eagle Pharmaceuticals Inc?
plus_minus_icon
What percentage is Eagle Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Eagle Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$31.16
$-0.66
(-2.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
WAVE LIFE SCIENCES LTD
WAVE LIFE SCIENCES LTD
$4.74
$-0.52 (-9.89 %)
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
$5.75
$-0.30 (-4.96 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.53
$-0.18 (-3.15 %)
Omeros Corporation
Omeros Corporation
$5.22
$0.09 (1.75 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
WAVE LIFE SCIENCES LTD
WAVE LIFE SCIENCES LTD
$4.74
$-0.52 (-9.89 %)
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
$5.75
$-0.30 (-4.96 %)
MacroGenics, Inc.
MacroGenics, Inc.
$5.53
$-0.18 (-3.15 %)
Omeros Corporation
Omeros Corporation
$5.22
$0.09 (1.75 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00